U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951411) titled 'Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.' on Nov. 16.

Brief Summary: This is a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial. The purpose of this study is to evaluate the efficacy and safety of SAL0167, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hyperlipidemia. Participants will be randomized 1:1:1:1 to receive low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo for a treatment period of 8 weeks.

Study Start Date: Dec. 31

Study Type: INTERVENTIONAL

Con...